COMPANY

Javelin Biotech Inc.

HQ: Billerica, MA source · javelinbiotech.com ↗ · New England

Location: Billerica, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

NIH awards 6

Annual award amounts. Total $4.3M.

Jun 16, 2026 NIH award 1R43TR005374-01A1 FY2026: $349,677 awarded for that fiscal year; activity R43 (SBIR); PI CIRIT, MURAT; recipient as written: JAVELIN BIOTECH, Billerica, MA. Investigating the Impact of Metabolic Disease Sta source ↗
Jul 26, 2024 NIH award 5R44TR004524-02 FY2024: $974,458 awarded for that fiscal year; activity R44 (SBIR); PI CIRIT, MURAT; recipient as written: JAVELIN BIOTECH, Billerica, MA. Hepatic Clearance Chip for Pharmacokinetics source ↗
Aug 30, 2023 NIH award 1R44TR004524-01A1 FY2023: $1,009,594 awarded for that fiscal year; activity R44 (SBIR); PI CIRIT, MURAT; recipient as written: JAVELIN BIOTECH, Billerica, MA. Hepatic Clearance Chip for Pharmacokinetics source ↗
Aug 18, 2022 NIH award 1R43TR004228-01 FY2022: $314,803 awarded for that fiscal year; activity R43 (SBIR); PI CIRIT, MURAT; recipient as written: JAVELIN BIOTECH, Billerica, MA. Multi-Tissue MAFLD Chip for Mechanism-Based Drug Te source ↗
Sep 21, 2021 NIH award 1R43GM143980-01 FY2021: $259,613 awarded for that fiscal year; activity R43 (SBIR); PI CIRIT, MURAT; recipient as written: JAVELIN BIOTECH, Billerica, MA. DDI-on-a-chip: an optimized liver microphysiologica source ↗
Aug 5, 2019 NIH award 7U24TR002634-02 FY2019: $1,435,688 awarded for that fiscal year; activity U24 (OTHER_NIH); PI CIRIT, MURAT; recipient as written: JAVELIN BIOTECH, Billerica, MA. Translational Center of Tissue Chip Technolo source ↗

NIH award NIH awarded $350K (SBIR Phase I 1R43TR005374-01A1, new, notice Jun 16, 2026). NIH RePORTER 1R43TR005374-01A1 (Jun 16, 2026)
Evidence (1 event)
- Jun 16, 2026 · NIH RePORTER 1R43TR005374-01A1
  Organization: JAVELIN BIOTECH; City/State: Billerica, MA; Project number: 1R43TR005374-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 349677; Administering IC: National Center for Advancing Translational Sciences; Project title: Investigating the Impact of Metabolic Disease States on the Pharmacodynamics and Toxicity of FDA-Approved Antisense Oligonucleotides Using an Integrated Liver-Kidney Model; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals